

# Vlidaplit 50 Tablet

## Composition (per uncoated tablet):

- **Vildagliptin** – 50 mg

## Description:

Vlidaplit 50 Tablet contains Vildagliptin, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus. It enhances the levels of incretin hormones (GLP-1 and GIP), leading to improved glucose-dependent insulin secretion and decreased glucagon secretion, thereby improving glycemic control.

## Indications:

- Type 2 Diabetes Mellitus (as monotherapy or in combination with other antidiabetic agents)
- Adjunct to diet and exercise to improve glycemic control

## Mechanism of Action:

Vildagliptin works by inhibiting the DPP-4 enzyme that degrades incretin hormones. This inhibition prolongs the action of GLP-1 and GIP, enhancing insulin release and suppressing glucagon secretion in a glucose-dependent manner, thereby reducing both fasting and postprandial glucose levels.

## Dosage and Administration:

- One tablet once or twice daily or as prescribed by the physician
- May be taken with or without food
- Dosage may need to be adjusted based on renal function and combination therapy

## Contraindications:

- Hypersensitivity to Vildagliptin or any excipients
- Type 1 diabetes or diabetic ketoacidosis

## Precautions:

- Use with caution in patients with moderate to severe renal impairment
- Monitor liver function periodically during treatment
- Not recommended in patients with hepatic dysfunction
- Inform physician of any signs of pancreatitis or skin disorders

## Side Effects:

- Headache, dizziness, constipation
- Rare: Hypoglycemia (more likely when used with sulfonylureas), hepatic dysfunction, pancreatitis, skin reactions

**Storage:**

- Store below 30°C in a dry place
- Protect from light and moisture
- Keep out of reach of children

Manufactured in India for:



**Cafoli Lifecare Pvt. Ltd.**

**(An ISO 9001: 2015 Certified Co.)**

Plot no.: 367-FF, Industrial Area Phase-I,  
Panchkula-134113

TM: Trademark Applied for